Plain-English translation of NCT07013110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing a new treatment called —a peptide derived from beneficial bacteria in your gut—combined with hydroxychloroquine, a medication already used to treat rheumatoid arthritis. The study will compare this combination to hydroxychloroquine alone in about 124 people who have moderate to severe rheumatoid arthritis and haven't yet tried other disease-modifying arthritis drugs. Researchers want to understand how the medication works and whether it can help your body develop lasting tolerance to arthritis rather than just suppressing your immune system.
Current arthritis medications work mainly by suppressing the immune system, which can have side effects and doesn't offer a true cure. This study explores whether this new treatment might help your immune system learn to tolerate arthritis naturally—potentially moving from temporary symptom control toward actual healing.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the new peptide medication plus hydroxychloroquine, or a placebo plus hydroxychloroquine—neither you nor the study staff will know which group you're in. You'll take your assigned medication by mouth once daily, ideally in the morning on an empty stomach. Throughout the trial, you'll attend scheduled visits for blood tests and assessments to measure your arthritis activity and help researchers understand how the treatment affects your immune system.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Singapore